1Bjornsson E, Jacobsen EI, Kalaitzakis E. ltepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing [J]. J Hepatol, 2012, 56(2) : 374-380.
2Ridruejo E, Mando OG. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin [J]. J Hepatol, 2002, 37 ( 1 ) : 165-166.
3Gershovich OE, Lyman AE. Liver function test abnormalities and pruritis in a patient treated with atorvastatin: case report and review of the literature[J]. Pharmacotherapy, 2004, 24 ( 1 ) :150- 154.
4Nelson R H.Hyperlipidemia as a risk factor for cardiovascular disease[J].Prim Care,2013,40(1):195-211.
5Mitra S,Deshmukh A,Sachdeva R,et al.Oxidized lowdensity lipoprotein and atherosclerosis implications in antioxidant therapy[J].Am J Med Sci,2011,342(2):135-42.
6Verhoye E,Langlois M R,Asklepios investigators.Circulating oxidized lowdensity lipoprotein:a biomarker of atherosclerosis and cardiovascular risk [J]? Clin Chem Lab Med,2009,47(2):128-37.
7Chan W W,Wong G T,Irwin M G.Perioperative statin therapy[J].Expert Opin Pharmacother,2013,14(7):831-42.
8Libby P.Inflammation in atherosclerosis[J].Arterioscler Thromb Vasc Biol,2012,32(9):2045-51.
9Tabas I,Glass C K.Anti-inflammatory therapy in chronic disease:challenges and opportunities[J].Science,2013,339(6116):166-72.
10Fischetti F,Tedesco F.Crosstalk between the complement system and endothelial cells in physiologic conditions and in vascular diseases[J].Autoimmunity,2006,39(5):417-28.
